Alvotech sees minimal impact on 2025 product revenues from tariffs
Source: SeekingAlpha
2025-05-07 06:20:23 ET
More on Alvotech
- Alvotech: Potential Victim Of Pharma Tariff Threats (Rating Downgrade)
- Alvotech (ALVO) Q4 2024 Earnings Call Transcript
- Alvotech 2024 Q4 - Results - Earnings Call Presentation
- Teva, Alvotech get FDA nod for Johnson & Johnson biosimilar
- Alvotech acquires Xbrane’s R&D operations in Sweden and biosimilar candidate XB003
Read the full article on Seeking Alpha
For further details see:
Alvotech sees minimal impact on 2025 product revenues from tariffs
Alvotech
NASDAQ: ALVO
ALVO Trading
-6.23% G/L:
$3.01 Last:
679,105 Volume:
$3.23 Open:
ALVO Latest News
May 11, 2026 04:30:00 am
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
ALVO Stock Data
$1,569,389,520
107,654,085
N/A
30
N/A
Pharmaceuticals
Healthcare
LU
Luxembourg
